A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 0.3 mg for the Treatment of Hot Flashes
NCT ID: NCT00272935
Last Updated: 2012-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
400 participants
INTERVENTIONAL
2005-12-31
2007-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Cenestin 0.3 mg Tablets
1 tablet daily
2
Placebo
1 tablet daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cenestin 0.3 mg Tablets
1 tablet daily
Placebo
1 tablet daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 12 months since last menses or 6 weeks past surgery
* Minimum of 7 daily or 50 weekly moderate to severe hot flashes
Exclusion Criteria
30 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Duramed Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Duramed Research, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Duramed Research Protocol Chair
Role: STUDY_CHAIR
Duramed Research, Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Duramed Investigational Site
Huntsville, Alabama, United States
Duramed Investigational Site
Montgomery, Alabama, United States
Duramed Investigational Site
Phoenix, Arizona, United States
Duramed Investigational Site
Phoenix, Arizona, United States
Duramed Investigational Site
Tucson, Arizona, United States
Duramed Investigational Site
Carmichael, California, United States
Duramed Investigational Site
Irvine, California, United States
Duramed Investigational Site
San Diego, California, United States
Duramed Investigational Site
San Diego, California, United States
Duramed Investigational Site
San Diego, California, United States
Duramed Investigational Site
San Ramon, California, United States
Duramed Investigational Site
Brooksville, Florida, United States
Duramed Investigational Site
Coral Gables, Florida, United States
Duramed Investigational Site
Gainesville, Florida, United States
Duramed Investigational Site
Leesburg, Florida, United States
Duramed Investigational Site
Miami, Florida, United States
Duramed Investigational Site
Palm Springs, Florida, United States
Duramed Investigational Site
Venice, Florida, United States
Duramed Investigational Site
Alpharetta, Georgia, United States
Duramed Investigational Site
Douglasville, Georgia, United States
Duramed Investigational Site
Boise, Idaho, United States
Duramed Investigational Site
Evansville, Indiana, United States
Duramed Investigational Site
Lexington, Kentucky, United States
Duramed Investigational Site
Baltimore, Maryland, United States
Duramed Investigational Site
Lincoln, Nebraska, United States
Duramed Investigational Site
Las Vegas, Nevada, United States
Duramed Investigational Site
Albuquerque, New Mexico, United States
Duramed Investigational Site
Cleveland, Ohio, United States
Duramed Investigational Site
Columbus, Ohio, United States
Duramed Investigational Site
Mayfield Heights, Ohio, United States
Duramed Investigational Site
Medford, Oregon, United States
Duramed Investigational Site
King of Prussia, Pennsylvania, United States
Duramed Investigational Site
North Wales, Pennsylvania, United States
Duramed Investigational Site
Philadelphia, Pennsylvania, United States
Duramed Investigational Site
Philadelphia, Pennsylvania, United States
Duramed Investigational Site
Pittsburgh, Pennsylvania, United States
Duramed Investigational Site
Charleston, South Carolina, United States
Duramed Investigational Site
Bristol, Tennessee, United States
Duramed Investigational Site
Clarksville, Tennessee, United States
Duramed Investigational Site
Nashville, Tennessee, United States
Duramed Investigational Site
Dallas, Texas, United States
Duramed Investigational Site
Fort Worth, Texas, United States
Duramed Investigational Site
Houston, Texas, United States
Duramed Investigational Site
Houston, Texas, United States
Duramed Investigational Site
Houston, Texas, United States
Duramed Investigational Site
San Antonio, Texas, United States
Duramed Investigational Site
Norfolk, Virginia, United States
Duramed Investigational Site
Spokane, Washington, United States
Duramed Investigational Site
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BR-CEN-301
Identifier Type: -
Identifier Source: org_study_id